Underhill Investment Management Lowered Its Brown Forman Cl B (BF.B) Holding; Hwg Holdings LP Has Cut Its Acadia Pharmaceuticalsinc Com (ACAD) Holding

December 11, 2017 - By Marie Mckinney

Hwg Holdings Lp decreased Acadia Pharmaceuticalsinc Com (ACAD) stake by 94.59% reported in 2017Q2 SEC filing. Hwg Holdings Lp sold 95,533 shares as Acadia Pharmaceuticalsinc Com (ACAD)’s stock declined 29.10%. The Hwg Holdings Lp holds 5,461 shares with $152,000 value, down from 100,994 last quarter. Acadia Pharmaceuticalsinc Com now has $3.71B valuation. The stock decreased 1.97% or $0.6 during the last trading session, reaching $29.89. About 511,296 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since December 11, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.

Underhill Investment Management Llc decreased Brown Forman Inc Cl B (BF.B) stake by 10.39% reported in 2017Q2 SEC filing. Underhill Investment Management Llc sold 25,850 shares as Brown Forman Inc Cl B (BF.B)’s stock 0.00%. The Underhill Investment Management Llc holds 222,900 shares with $10.83M value, down from 248,750 last quarter. Brown Forman Inc Cl B now has $25.24 billion valuation. The stock decreased 0.93% or $0.62 during the last trading session, reaching $65.86. About 366,604 shares traded. Brown-Forman Corporation (NYSE:BF.B) has risen 11.07% since December 11, 2016 and is uptrending. It has underperformed by 5.63% the S&P500.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on February, 27. They expect $-0.59 earnings per share, up 9.23% or $0.06 from last year’s $-0.65 per share. After $-0.53 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 11.32% negative EPS growth.

Investors sentiment decreased to 1.01 in 2017 Q2. Its down 0.04, from 1.05 in 2017Q1. It dived, as 31 investors sold ACAD shares while 54 reduced holdings. 21 funds opened positions while 68 raised stakes. 115.85 million shares or 0.73% less from 116.70 million shares in 2017Q1 were reported. York Mngmt Glob Advsr Llc has 120,004 shares for 0.07% of their portfolio. 19,112 are held by State Of Wisconsin Board. Jefferies Gp Lc holds 46,000 shares or 0.01% of its portfolio. Columbus Circle Invsts reported 175,149 shares. Prudential Fincl reported 184,460 shares. Moreover, Amalgamated Bancorporation has 0.02% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Baker Bros Limited Partnership reported 6.3% stake. California State Teachers Retirement System invested in 172,137 shares or 0.01% of the stock. State Street holds 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 3.75 million shares. Next Fincl Group Inc invested in 200 shares or 0% of the stock. Tower Capital Limited Liability Com (Trc) has invested 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Great West Life Assurance Can invested in 11,789 shares or 0% of the stock. Grp Inc One Trading LP owns 281,806 shares or 0.08% of their US portfolio. Ubs Asset Management Americas Inc reported 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Walleye Trading Ltd Limited Liability Company owns 338 shares.

Hwg Holdings Lp increased Apple Inc (NASDAQ:AAPL) stake by 5,095 shares to 17,913 valued at $2.58M in 2017Q2. It also upped Facebook Inc Com Usd0.000006Cl (NASDAQ:FB) stake by 3,477 shares and now owns 8,696 shares. Ishares Russell 1000Value Etf (IWD) was raised too.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. On Thursday, October 5 the stock rating was maintained by J.P. Morgan with “Buy”. The rating was maintained by Needham on Friday, August 7 with “Buy”. Jefferies maintained the stock with “Buy” rating in Monday, September 4 report. The stock has “Mkt Perform” rating by Leerink Swann on Tuesday, October 4. The firm has “Buy” rating given on Tuesday, October 10 by Jefferies. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by J.P. Morgan on Wednesday, November 8. H.C. Wainwright maintained the shares of ACAD in report on Wednesday, November 8 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, October 5. Roth Capital reinitiated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Wednesday, October 19 with “Neutral” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Overweight” rating given on Friday, January 22 by Piper Jaffray.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>